S. S. Sridhar

Learn More
Approximately 20%-25% of all breast cancers over express a key cell surface growth factor receptor known as HER2. HER2 plays a key role in cell growth and proliferation and is linked to worse clinical outcomes, making it a logical therapeutic target. The first HER2 targeted drug to be approved by the FDA, was the humanized monoclonal antibody trastuzumab,(More)
BACKGROUND The association between age and outcomes in men with castrate resistant prostate cancer (CRPC) is not well understood. OBJECTIVE We aimed to evaluate CRPC patients to determine if their age at initial diagnosis impacted their cancer specific outcomes. DESIGN, SETTING, AND PARTICIPANTS A retrospective chart review was conducted on 333(More)
BACKGROUND First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.(More)
BACKGROUND We sought to determine which parsimonious combination of complete blood count (CBC)-based biomarkers most efficiently predicts oncologic outcomes in patients undergoing radical cystectomy (RC) for bladder cancer (BC). METHODS Using our institutional RC database (1992-2012), nine CBC-based markers (including both absolute cell counts and ratios)(More)
Background: Benefits of adjuvant chemotherapy (AC) and extent of pelvic lymph node dissection (PLND) in radical cystectomy (RC) are debated. Results from randomized trials are still expected. Objective: To analyze the effects of AC and PLND in two academic centers with opposite policies regarding their use. Methods: 581 bladder cancer patients who underwent(More)
  • 1